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Abstract
Background: Rapid and effective treatment of cancer-induced bone pain remains a clinical challenge and patients 
with bone metastasis are more likely to experience severe pain. The voltage-gated sodium channel Nav1.8 plays a 
critical role in many aspects of nociceptor function. Therefore, we characterized a rat model of cancer pain and 
investigated the potential role of Nav1.8.
Methods: Adult female Wistar rats were used for the study. Cancer pain was induced by inoculation of Walker 256 
breast carcinosarcoma cells into the tibia. After surgery, mechanical and thermal hyperalgesia and ambulation scores 
were evaluated to identify pain-related behavior. We used real-time RT-PCR to determine Nav1.8 mRNA expression in 
bilateral L4/L5 dorsal root ganglia (DRG) at 16-19 days after surgery. Western blotting and immunofluorescence were 
used to compare the expression and distribution of Nav1.8 in L4/L5 DRG between tumor-bearing and sham rats. 
Antisense oligodeoxynucleotides (ODNs) against Nav1.8 were administered intrathecally at 14-16 days after surgery to 
knock down Nav1.8 protein expression and changes in pain-related behavior were observed.
Results: Tumor-bearing rats exhibited mechanical hyperalgesia and ambulatory-evoked pain from day 7 after 
inoculation of Walker 256 cells. In the advanced stage of cancer pain (days 16-19 after surgery), normalized Nav1.8 
mRNA levels assessed by real-time RT-PCR were significantly lower in ipsilateral L4/L5 DRG of tumor-bearing rats 
compared with the sham group. Western-blot showed that the total expression of Nav1.8 protein significantly 
decreased bilaterally in DRG of tumor-bearing rats. Furthermore, as revealed by immunofluorescence, only the 
expression of Nav1.8 protein in small neurons down regulated significantly in bilateral DRG of cancer pain rats. After 
administration of antisense ODNs against Nav1.8, Nav1.8 protein expression decreased significantly and tumor-bearing 
rats showed alleviated mechanical hyperalgesia and ambulatory-evoked pain.
Conclusions: These findings suggest that Nav1.8 plays a role in the development and maintenance of bone cancer 
pain.
Background
Rapid and effective treatment of cancer-induced bone
pain that diminishes the quality of life of affected patients
remains a clinical challenge. Metastasis of tumor cells to
bone is particularly common in patients with lung,
breast, and prostate cancer [1]. The presence of bone
metastases predicts the occurrence of pain and is the
most common cause of cancer-related pain. Although
bone metastases do not involve vital organs, they may
have deleterious effects in patients with prolonged sur-
vival. The greatest obstacle to the development of new
treatments for cancer pain is our limited knowledge of
the basic neurobiological mechanisms that lead to cancer
pain [2]. Recently, breast cancer, prostate cancer and sar-
coma cells were used to successfully induce cancer pain in
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Page 2 of 10rats. These models have furthered our understanding of
the mechanisms underlying cancer pain.
Voltage-gated sodium channels (VGSCs) are essential
in regulating the excitability of neurons and significant
changes in the expression of these channels can produce
abnormal spontaneous firing patterns that can lead to
chronic pain [3,4]. Sensory neurons express several
VGSC subunits with fast (e.g. Nav1.3 and Nav1.7) or slow
(Nav1.8 and Nav1.9) kinetics [5-8]. Whereas fast VGSCs
are selectively blocked by the puffer-fish poison tetrodo-
toxin (TTX), both Nav1.8 and Nav1.9 are resistant to
TTX (TTX-R). Nav1.8, formerly called the sensory neu-
ron-specific or the peripheral nerve sodium channel type
3, is expressed exclusively in sensory neurons and is not
found in the central nervous system (CNS) [5]. Nav1.8
channels produce the majority of the inward current dur-
ing the action potential (AP) upstroke in the dorsal root
ganglion (DRG) neurons in which they exist [9], most of
which are nociceptors [10]. Changes in the expression,
trafficking, and redistribution of Nav1.8 in chronic pain
models are considered to account for abnormal firing and
the generation of ectopic activity in afferent nerves [11].
Carrageenan-induced inflammatory pain increases
Nav1.8 mRNA expression and the density of TTX-R cur-
rents [12]. Peripheral axotomy results in a decrease in the
expression of functional Nav1.8 channels and TTX-R
currents in C-type DRG neurons, suggesting a basis for
the altered electrical properties observed after peripheral
nerve injury [13]. Moreover, antisense oligonucleotide-
mediated in vivo knockdown of Nav1.8 after intrathecal
administration leads to a marked decrease in neuropathic
[14] and inflammatory pain [15]. Genetic engineering
approaches revealed a critical role of NaV1.8 in mediating
pathologic pain: Nav1.8 knockout mice exhibited pro-
nounced analgesia to noxious mechanical stimuli and
delayed development of inflammatory hyperalgesia while
exhibiting generally normal behavior [16]. However, the
Nav1.8 null mice showed normal hyperalgesia in the early
days after partial ligation of sciatic nerve[17]. It was
recently reported that a Nav1.8-selective compound (A-
803467) produces significant antinociception in animal
models of neuropathic and inflammatory pain, implying
that Nav1.8-targeted chronic pain therapy should be fea-
sible [18]. These results indicate that Nav1.8 plays an
important role in nociception and raise the possibility
that it is involved in chronic cancer pain. However, the
expression of Nav1.8 and the role it plays in cancer pain
are still unclear.
In this study, we hypothesized that Nav1.8 contributes
to nociceptive hypersensitivity in a cancer pain model
induced by bone metastases of Walker 256 breast carci-
nosarcoma cells. To test this hypothesis, we examined
Nav1.8 mRNA levels and protein expression in DRG of
rats with tumors. Moreover, antisense oligodeoxynucle-
otides (ODNs) against Nav1.8 were administered intrath-
ecally to knock down Nav1.8 expression and explore the
effect on pain-related behavior.
Methods
Animals
All experiments were performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals
and the Ethical Issues of the IASP [19] and were approved
by the Second Military Medical University Committee on
Animal Care. Adult female Wistar rats (200-250 g) used
for the study were housed under a 12-h light/dark cycle in
a pathogen-free area with ad libitum access to water and
food.
Preparation of Walker 256 cells
Walker 256 carcinosarcoma breast cancer cells were
kindly provided by the Shanghai Institute of the Pharma-
ceutical Industry. They were prepared and developed as
previously described [20]. In brief, Walker 256 tumor
cells were obtained from an ascitic tumor-bearing rat and
collected by centrifugation of 2 mL of ascitic fluid for 3
min at 1200 rpm. The resulting pellet was washed twice
with 10 mL of Dulbecco's modified Eagle medium (Bio-
source, Camarillo, CA, USA). The final pellet was resus-
pended in 3 mL of PBS solution and cells were counted
using a hemocytometer and trypan blue solution. Cells
were diluted to the final concentration for injection and
kept on ice. For the sham group, Walker 256 cells were
prepared at the same final concentrations for injection
and boiled for 20 min.
Induction of bone cancer
Animals subjected to tumor cell implantation were anes-
thetized by intraperitoneal injection of sodium pentobar-
bital (40 mg/kg). The left leg was shaved and the skin was
disinfected with 70% (v/v) ethanol. A 1-cm-long rostro-
caudal incision was made in the skin over the lower one-
third of the tibia for easy exposure with minimal damage
to muscles and nerves. The medullary canal was
approached by inserting a 23-gauge needle proximally
through a hole drilled in the tibia. The needle was then
replaced with a 20-μL microinjection syringe containing
the cells to be injected. A 10-μL volume of Walker 256
cells (2 × 105 cells) or boiled cells (sham group) was
injected into the bone cavity. After a 2-min delay to allow
cells to fill the bone cavity, the syringe was removed and
the drill hole was sealed using bone wax. The wound was
closed using 1-0 silk threads and dusted with penicillin
powder. The rats were allowed unrestricted movement in
their cages after recovery and their general condition was
monitored during the experiment.
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Rats were anesthetized and an intrathecal catheter was
inserted according to the method of Storkson et al. [21].
In brief, a PE-10 polyethylene catheter was implanted
into the subarachnoid space between the L5 and L6 verte-
brae to reach the lumbar enlargement of the spinal cord
at a depth of 1.5-2 cm. The outer part of the catheter was
plugged and fixed onto the skin on closure of the wound.
The incision was sutured at all levels and 2000 U of peni-
cillin was administered to prevent infection. Animals
were observed for 3 days after catheter insertion and
those without any obvious change in movement were
chosen for intrathecal administration. A Nav1.8 antisense
ODN (5-GGG GAG CTC CAT CTT CTC-3) (Integrated
DNA Technologies, Coralville, IA) was directed against a
unique sequence of the Nav1.8 sodium channel [22]. The
mismatch ODN sequence, 5-GGG GTC TTC CAA GCT
CTC-3, was derived from the antisense sequence by
scrambling six bases (denoted in bold font). ODNs were
lyophilized and reconstituted in 0.9% NaCl prepared with
nuclease-free water to a concentration of 2 μg/μL. ODNs
or saline were intrathecally injected via the implanted
catheter in a 10-μL volume of solution followed by 15 μL
of saline for flushing. Daily intrathecal administration
started on day 14 after tumor inoculation for 3 days and
pain behavior was assessed every 2 or 3 days.
Mechanical hyperalgesia test
To assess mechanical hyperalgesia, animals were accli-
mated daily for 10 min/day for 3 days to the test environ-
ment, which was a Plexiglass box on a metal grid surface.
On test days, rats were allowed to acclimate for 5-10 min.
The nociceptive stimulus, a single rigid filament attached
to a hand-held transducer (electronic Von Frey anesthesi-
ometer; IITC, Woodland Hills, CA) was applied perpen-
dicularly to the medial surface of the hind paw with
increasing force. The endpoint was taken as nocifensive
paw withdrawal accompanied by head turning, biting
and/or licking. As soon as this reaction occurred, the
required pressure was indicated in grams, and this value
was considered to be the individual paw withdrawal
threshold (PWT) value. Both hind limbs of each rat were
tested in triplicate per time point and the average for the
three measurements was then calculated.
Hargreaves test
Paw withdrawal latency (PWL) was measured for both
paws as previously described [23] before any procedure.
In brief, rats were placed under an inverted clear plastic
chamber on a glass surface. After an adaptation period of
30 min, a radiant heat stimulus was applied to the plantar
surface of each hind paw from underneath the glass floor
using a projector lamp bulb (automatic plantar analgesia
tester; Institute of Biomedical Engineering, Chinese
Academy of Medical Science, Tianjin, China). The radi-
ant heat intensity was adjusted so that the PWL for nor-
mal rats was 10 ± 2 s. A cutoff time of 20 s was imposed
to prevent tissue damage. Paws were alternated randomly
to preclude order effects and PWL was determined as the
mean of three measurements per paw.
Ambulatory-evoked pain
Rats were placed in a large plastic observation box with a
smooth floor. According to the extent of limb use during
spontaneous ambulation, scores were characterized as
follows: 0, normal use; 1, slight limp; 2, severe limp; or 3,
complete lack of limb use. Testing was blind with respect
to group.
Immunofluorescence
Rats were anesthetized and perfused transcardially with
normal saline followed by 4% paraformaldehyde in 0.1
mol/L phosphate buffer (pH 7.4) at 16-19 days after
Walker 256 cell inoculation or 1 day after intrathecal
administration. L4/L5 DRG were immediately dissected
and postfixed in 4% paraformaldehyde in 0.1 M PBS, pH
7.2 for 2-4 h. The DRG were then transferred to 30%
sucrose in PBS and kept in the solution until they sank to
the bottom. Sections (7 μm) were cut using a Leica
CM1900 cryostat and thaw-mounted in series on 10
slides, with each slide containing 6-8 sections at different
levels throughout the DRG. Slides were washed in PBS,
blocked in 10% normal horse serum (NHS) in PBS for 30
min and incubated with polyclonal rabbit anti-Nav1.8
antibody (Chemicon, CA, USA) diluted 1:200 in antibody
dilution solution (10% NHS and 0.4% sodium azide in
PBS) overnight. The sections were then incubated in
FITC-conjugated donkey anti-rabbit IgG (Jackson Immu-
noResearch Lab, West Grove, PA) at a dilution of 1:400 in
antiserum diluent. Images were recorded using a
DXM1200 digital camera (Nikon, Japan) attached to an
Eclipse E600 microscope (Nikon). Images were imported
into Adobe Photoshop CS3. The Nav1.8 immunocy-
tochemical intensity was measured using a semiquantita-
tive method [10]. In brief, the total area of a neuron or
cytoplasm was manually selected and the neuronal cross-
sectional area (including the nucleus) and mean pixel
density for immunostaining in the cytoplasm (excluding
the nucleus) were determined by the software. For each
image, the relative intensity for each neuron was calcu-
lated using the normalized method previously described
[24] and a relative intensity of 20% was used as the
threshold to discriminate between negative and positive
neurons. As defined previously [25], neurons with a
cross-sectional area of up to 400 μm2 were classified as
small (diameter 23 μm), those of >800 μm2 (diameter 32
μm) as large, and those of 400-800 μm2 (diameter 23-32
μm) as medium-sized.
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Rats were deeply anesthetized with 40 mg/mL sodium
pentobarbital and killed by decapitation at 16-19 days
post surgery. L4/L5 DRG were removed, homogenized
and lysed in a solution of 2% SDS, 20% glycerol, and 100
mM Tris-HCl, pH 6.8 containing Complete protease
inhibitor (Roche Diagnostics, Rotkreuz, Switzerland).
The homogenate was centrifuged for 10 min at 10,000
rpm at 4°C, the supernatant was recovered and the pro-
tein concentration was determined by the Bradford
method. The sample was diluted in sample buffer (250
mm Tris-HCl, pH 6.8 containing 4% SDS, 10% glycerol,
2% β-mercaptoethanol, and 0.002% bromophenol blue)
and boiled for 10 min. A sample aliquot was separated by
SDS-PAGE (10%) and then transferred to a nitrocellulose
membrane by electroblotting. The membrane was
blocked in 5% skim milk powder in 0.1% Tris-buffered
saline/Tween 20 at room temperature for 2 h, and then
incubated with antibody raised against Nav1.8 (Chemi-
con Int., CA, USA) at a dilution of 1:500 overnight at 4°C.
Antibody binding was visualized using a horseradish per-
oxidase-conjugated secondary antibody and an enhanced
chemiluminescence Western blotting detection system
(Santa Cruz Biotechnology, Santa Cruz, CA). Light-emit-
ting bands were detected using X-ray film. The band
intensities were quantitated using an image scanning
densitometer (Furi Technology, Shanghai, China). To
control sampling errors, the Nav1.8/β-actin band inten-
sity ratio was obtained to quantify relative protein expres-
sion levels.
Total RNA extraction and quantitative real-time RT-PCR
Tumor-bearing and sham rats were deeply anaesthetized
and killed by decapitation at 14-18 days post surgery. L4/
L5 DRG were collected and mechanically dispersed by
scraping with a rubber policeman for 1 min in the pres-
ence of TRIzol reagent (Invitrogen, Grand Island, NY)
and then incubated for 5 min at the room temperature for
complete nucleoprotein dissociation. Total RNA was pre-
pared from individual samples using TRIzol reagent
according to the manufacturer's instructions. The purity
and integrity of the RNA were checked spectroscopically
and by gel electrophoresis before use. A sample of 2 μg of
RNA was reverse transcribed with oligo (dT)18 primer
using Moloney murine leukemia virus reverse tran-
scriptase (Promega, Madison, WI, USA). The primer
sequences for Nav1.8 were: sense, 5'-GGA CTC CCT
GAA GAC CAA TAT GGA AG-3'; antisense 5'-GCA
TTG AGC TAG ATG GGT TAA TGT TG-3'. This should
amplify a fragment of 361 bp corresponding to nucle-
otides 5479-5840 of the Nav1.8 coding region (GenBank
accession number U53833). Quantitative real-time PCR
analysis was carried out using a Rotor Gene 3000 system
(Corbett Research, Sydney, Australia). The reaction solu-
tion consisted of 2.0 μL of diluted cDNA product, 0.2 μM
of each paired primer, 200 μM deoxynucleotide triphos-
phates, 1 U of Taq DNA polymerase (Promega), and 1×
PCR buffer. SYBR Green dye (BMA, Rockland, ME, USA)
was used for detection. PCR conditions were optimized
in a preliminary experiment to achieve a linear relation-
ship between the initial RNA concentration and the PCR
product. The annealing temperature was 55-58°C and 40
amplification cycles were carried out. The range for
detection of the melting temperature of the PCR product
was 60-95°C. Amplification of the housekeeping gene β-
actin was measured for each sample as an internal PCR
control for sample loading and normalization. The speci-
ficity of the primers was verified by examining the melt-
ing curve and subsequent sequencing of the real-time
PCR products. To quantitate the relative amount of gene
expression for the target and housekeeping genes, the
comparative threshold cycle (Ct) method was used. Sub-
tracting Ct for the housekeeping gene from Ct for the tar-
get gene yields ΔCt in each group (control and
experimental groups), which was entered into the equa-
tion 2-ΔCt and calculated for exponential PCR amplifica-
tion. Nav1.8 mRNA levels were normalized relative to β-
actin values to ensure that a linear relationship between
the initial RNA concentration and the PCR product was
achieved in each run.
Data analysis
Data from most assays were analyzed using one-way
measures analysis of variance (ANOVA) followed by
post-hoc Scheffe's multiple comparisons. Immunofluo-
rescence data were analyzed by χ2 test. P < 0.05 was set as
the level of statistical significance in all cases.
Results
General observations
All animals displayed general good health with no signs
of distress during the 21-day observation period. Signs of
tumor growth, observed as swelling around the tibia,
became visible in most cancer animals by day 14. As
shown in a related study in this issue [20], Walker 256
carcinoma causes progressive destruction of the calca-
neus bone by this time.
Tumor inoculation-induced pain model
There was no evidence of ambulatory pain in animals
that received a sham injection. By contrast, animals
injected with Walker 256 carcinoma cells exhibited an
apparent limp on the injected hind limb over days follow-
ing injection. A significant (P < 0.01) decrease in ipsilat-
eral limb use by tumor-bearing rats was observed from
day 10 after surgery (Fig. 1A).
Tumor-bearing rats showed pronounced curling of the
toes, cupping and guarding of the ipsilateral paw, and a
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hind paw during normal ambulation on a metal grid sur-
face as part of the mechanical hyperalgesia test. The base-
line PWT was 59.8 ± 7.5 and 62.9 ± 5.8 g for the left and
right hind paw, respectively. After Walker 256 cell inocu-
lation, the PWT of both paws decreased progressively
(Fig. 1B, C). Post-hoc mean comparisons revealed that
cancer cell inoculation of the tibia induced a significant
(P < 0.01) decrease in PWT for the ipsilateral hind paw
from day 7 after surgery. The PWT for the contralateral
hind paw of tumor-bearing rats changed slightly but sig-
nificantly from day 17 (P < 0.05) compared to the normal
group, suggesting the development of mirror-image pain.
Rats injected with heat-killed cells showed no changes in
PWT for both hind paws.
No significant (P > 0.05) thermal hyperalgesia was
observed in tumor-bearing rats on either side compared
with sham or normal rats. These findings are in agree-
ment with previous reports [20,26].
Downregulation of Nav1.8 in cancer pain rats
We used real-time RT-PCR to compare Nav1.8 mRNA
expression in L4/L5 DRG 16-19 days after injection (Fig.
2A). Nav1.8 transcript levels were normalized to β-actin
and expressed as the ratio of the Nav1.8 level in DRG
from tumor-bearing or sham rats to the level in DRG
from normal rats. Injection of Walker 256 cells resulted
in significant downregulation of Nav1.8 mRNA in bilat-
eral DRG of tumor-bearing rats compared with the sham
group (P < 0.05). In sham animals, no significant changes
were observed in Nav1.8 mRNA expression compared to
normal rats (normal data not shown).
Western blotting (Fig. 2B) revealed a significant
decrease in relative Nav1.8 protein levels (percentage of
normal) in bilateral DRG of tumor-bearing rats (65.6 ±
4.9 and 78.2 ± 5.4 for ipsilateral and contralateral respec-
tively) compared to the sham group (P < 0.01). Moreover,
a post hoc test revealed that Nav1.8 protein expression on
the ipsilateral side of tumor-bearing rats was significantly
downregulated (P < 0.05) compared with the contralat-
eral side.
In addition, we investigated changes in Nav1.8 distribu-
tion in DRG by immunofluorescence 16-19 days after
injection. Nav1.8 expression was lower in tumor-bearing
rats than in the sham group (Fig. 3). Since no differences
were observed between sham and normal rats, we choose
normal rats as the control group in the next semiquanti-
tative analysis. Histograms for neurons (Fig. 4) showed
the cell area and Nav1.8 immunofluorescence relative
intensity. semiquantitative analysis showed the percent-
age of Nav1.8 immunofluorescent positive (>20% maxi-
mum intensity) cells in small, medium and large DRG
neurons. There was a significant decrease (P < 0.01) in
Figure 1 Time course of pain-related behavior in rats of the Walk-
er 256 group (n = 10), the sham group (n = 10) and the normal 
group (n = 8). (A) The ambulatory score increased on days 10, 14, 17 
and 21 after intra-tibial injection of Walker 256 carcinoma cells but not 
after injection of heat-killed cells. Data are expressed as mean ± SD. **P 
< 0.01 compared to normal rats. (B) After Walker 256 carcinoma cell in-
oculation, the PWT for the inoculated hind paw progressively de-
creased as revealed by electronic Von Frey filament stimulus. Data are 
mean ± SD. **P < 0.01 compared to normal rats. (C) The PWT for the 
contralateral hind paw of tumor-bearing rats changed slightly but sig-
nificantly on days 17 and 21 Data are expressed as mean ± SD. **P < 
0.01 (ANOVA) compared to normal rats.
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eral DRG from the tumor-bearing group accompanied by
advanced cancer pain compared to the sham group; the
decrease was from 86.9% to 74.0% for the ipsilateral side
and to 79.0% for the contralateral side. However no
effects were observed in the percentage of Nav1.8-posi-
tive cells in medium and large neurons.
Knockdown of Nav1.8 attenuates cancer pain behavior
The expression of Nav1.8 in DRGs decreased in cancer
pain rats, which is similar to those in neuropathic mod-
els[11,13,14]. Therefore we decided to knockdown
Nav1.8 referring to the study approaches of Nav1.8 in
neuropathic pain models[14].
To verify the effect of antisense ODNs, Nav1.8 expres-
sion in L4/L5 DRG was measured following intrathecal
delivery of ODNs or saline once daily for 3 days. Immun-
ofluorescence analysis revealed that antisense, but not
mismatch, ODNs significantly decreased Nav1.8 immu-
noreactivity in DRG compared with saline control rats
(Fig. 5). The resulting data confirm that Nav1.8 expres-
sion in DRG can be significantly downregulated by anti-
sense ODN treatment.
The functional consequences of Nav1.8 knockdown by
antisense ODNs were evaluated in pain-related behav-
ioral tests (Fig. 6). The absence of any abnormal behav-
ioral characteristics during ODN treatment demonstrates
that the ODN dosage and the various sequences used did
not precipitate any non-specific, sequence-independent,
ODN-mediated behavioral toxicity. Nav1.8 knockdown
had no effect on the CNS and other organ systems, as
Nav1.8 is expressed exclusively in primary afferent neu-
rons.
Neither antisense nor mismatch ODNs to Nav1.8 had
any effect on ambulatory pain in sham-operated rats. In
Figure 2 Regulation of Nav1.8 mRNA and protein levels in bilater-
al DRG of tumor-bearing and sham rats. (A) Relative quantification 
(triplicate analysis of 4-6 rats for each time point) by real-time RT-PCR 
revealed a significant decrease in Nav1.8 mRNA in bilateral DRG of tu-
mor-bearing rats compared with the sham group. (B) Western blots re-
vealed a significant decrease in bilateral DRG of tumor-bearing rats 
compared with the sham group. Moreover, Nav1.8 protein expression 
was significantly downregulated on the ipsilateral side compared with 
the contralateral side of tumor-bearing rats. Data are expressed as 
mean ± SD. *P < 0.05 (one-way ANOVA) compared with sham rats.
Figure 3 Representative images of Nav1.8 immunofluorescence 
in bilateral DRG from rats of the Walker 256 group, the sham 
group and the normal group. (A) Ipsilateral and (B) contralateral DRG 
from a tumor-bearing rat. (C) Ipsilateral and (D) contralateral DRG from 
a sham rat. (E) Ipsilateral and (F) contralateral DRG from a normal rat. 
Note that Nav1.8 expression in tumor-bearing rats decreased com-
pared to the normal group, although it is not clear from a simple vision 
inspection whether expression was lower on the ipsilateral or the con-
tralateral side, highlighting the need for quantitative analysis. Scale bar, 
50 μm.
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the response of sham-operated rats to nociceptive
mechanical or thermal stimuli, as revealed by mechanical
hyperalgesia and Hargreaves tests.
In rats with cancer pain induced by breast cancer cell
inoculation, treatment with mismatch ODNs had no sig-
nificant effect on pain-related behavior. By contrast, anti-
sense ODN administration reversed ambulatory pain
scores (P < 0.05) and PWT (P < 0.05) on the ipsilateral
side from approximately 2 days after administration. The
analgesia effect disappeared on the second day after the
last antisense ODN administration. PWT on the contral-
ateral side increased after antisense ODN administration,
but only reached significance on the first day after the last
administration. No changes in thermal PWL were
observed after antisense ODN administration in rats with
cancer pain.
Discussion
This study shows that further reduction of Nav1.8
reduced hypersensitivity and pain. Nav1.8 mRNA and
protein levels decreased in ipsilateral DRG neurons, espe-
cially in small neurons, concomitantly with the occur-
rence of stable ambulatory-evoked pain and mechanical
hyperalgesia. Moreover, antisense, but not mismatch,
ODNs to Nav1.8 administered by intrathecal injection
alleviated established pain-related behavior in tumor-
bearing rats. This decrease in nociceptive sensitivity was
accompanied by a significant decrease in Nav1.8 in DRG
neurons after injection of antisense ODNs to Nav1.8.
These results lend further credence to earlier conclu-
sions that Nav1.8 plays a critical role in many aspects of
nociceptor function [14,27-30]. Different Nav1.8 expres-
sion patterns have been observed in different animal
models of chronic peripheral pain, including bone cancer
pain induced by inoculation of breast cancer cells in rats.
Figure 4 Cell area and relative Nav1.8 immunofluorescence intensity. Histograms for neurons in tumor-injected (A) ipsilateral (n = 521), (B) con-
tralateral (n = 449) and (C) normal DRG (n = 549). Grey and black denote neurons with Nav1.8 immunofluorescence relative intensity >20% and >50%, 
respectively. Neurons are divided into small (cross-sectional area <400 μm2, diameter 23 μm), medium (400-800 μm2, diameter 23-32 μm) and large 
(>800 μm2, diameter 32 μm). (D) Semiquantitative analysis of the percentage of Nav1.8 immunofluorescent-positive (>20% relative intensity) cells in 
small, medium and large DRG neurons. The percentage of positive small neurons is significantly (P < 0.01) lower in tumor-injected bilateral DRG com-
pared to the normal group. No differences are evident for medium and large neurons. *P < 0.01 (χ2 test) compared to normal rats.
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neurons in rats with cancer pain is similar to that in rats
with peripheral neuropathic pain, suggesting the impor-
tance of a neuropathic element in bone cancer pain.
Tumor-induced injury of sensory nerve fibers has been
observed in ipsilateral DRG of tumor-bearing mice [31],
suggesting that afferent nerve injury in a manner mimick-
ing neuropathic pain is a probable cause of the decreased
ipsilateral expression of Nav1.8.
In this cancer pain model of rats, the contribution of
the Nav1.8 channel activity to the maintenance of cancer
pain does not appear to be directly related to an enhanced
synthesis of Nav1.8 in the primary afferent nerve. The
physiological properties of the TTX-resistant persistent
current associated with Nav1.8, which include a broad
overlap between activation and steady-state inactivation
centered close to resting potential, suggest that Nav1.8
contribute a depolarizing influence to resting poten-
tial[13], which in some cases, lead to a spontaneous man-
ner of fire in the absence of stimulation which probably
contribute to the maintenance of cancer pain. In addtion,
Nav1.8 activity is likely to be up-regulated through other
post-translational regulatory mechanisms such as the dis-
tribution of the channel proteins or protein phosphoryla-
tion[14]. It was also noted that after cancer-induced
Figure 5 Representative photomicrographs of Nav1.8 immuno-
fluorescence in DRG from cancer and sham rats after ODN injec-
tion. DRG contained significantly fewer Nav1.8-positive neurons in 
animals that received antisense ODNs (A-C) compared with animals 
that received mismatch ODNs (D-F). Scale bar, 50 μm.
Figure 6 Time course of pain-related behavior in rats after in-
trathecal injection of antisense or mismatch ODNs. (A) Antisense, 
but not mismatch, ODNs to Nav1.8 administered by intrathecal injec-
tion alleviated ambulatory-evoked pain in cancer rats. There were no 
changes in ambulatory-evoked pain scores in sham rats that received 
antisense ODNs. Ambulatory-evoked pain scores were reversed by ap-
proximately 48 h after antisense ODN administration and returned on 
the second day after the last Nav1.8 antisense ODN injection (n = 7 
each group). Consistently, antisense, but not mismatch, ODNs to 
Nav1.8 administered by intrathecal injection alleviated established 
mechanical hyperalgesia in ipsilateral (B) and contralateral (C) paws of 
in cancer rats. Mechanical hyperalgesia was reversed by approximately 
48 h after the antisense ODN administration. The hyperalgesia re-
turned on the second day after the last Nav1.8 antisense ODN injec-
tion.
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Page 9 of 10injury to sensory neurons, areas of the spinal cord and
CNS involved in the processing of somatosensory infor-
mation undergo various neurochemical and cellular
changes, known as central sensitization, that facilitate the
transmission and conscious awareness of both noxious
and non-noxious sensory information [32]. Nav1.8 down-
regulation might also be a negative feedback effect of the
CNS in a persistent severe chronic pain state.
However, we also observed downregulation of Nav1.8
in contralateral DRG neurons in tumor rats. Since no
inoculation was applied to the contralateral limb, the
tumorigenic component of bone cancer pain might con-
tribute to this alteration. Intracellular Nav1.8 domains
interact widely with many proteins and immunoprecipi-
tation assays have confirmed that some of these proteins
may regulate Nav1.8 in vivo [32]. Algogens released from
a tumor or its surrounding tissue and transported all over
the body, such as endothelin-1 [33], prostaglandins [34]
and ATP [35], may directly or indirectly sensitize and/or
excite primary afferent nociceptors and therefore interact
with the proteins that regulate Nav1.8. In addition, meta-
bolic abnormality induced by tumor development can
lead to changes in sodium channel expression.
Several studies have attempted to model bone cancer
pain by injecting tumor cells into the marrow space of the
rodent femur or tibia. According to the model induced by
Walker 256 breast carcinosarcoma cells described previ-
ously [20], we established a modified model by injecting
cells into the lower tibia instead of the intercondylar emi-
nence to avoid joint injury and for surgical precision.
Tumor-bearing rats showed progressive mechanical allo-
dynia and ambulatory-evoked pain indicative of clinical
bone cancer pain.
Different tumor cells injected into bone lead to a dis-
tinct pattern of cancer-related pain behavior, skeletal
destruction and neurochemical changes in the spinal
cord [36]. In the current study, mechanical allodynia was
observed after injection of Walker 256 cells not only in
the ipsilateral hind paw, but also in the contralateral paw
from day 17. These findings are in agreement with previ-
ous observations that mirror-image pain occurs in this
model [20]. By contrast, no signs of mirror-image pain
were observed in another model of cancer pain induced
by injection of Walker 256 cells into the plantar surface of
rat hind paw [26]. The reason for these differences may
be that the observation period for the latter was too short
(from baseline to 5-8 days after surgery) since mirror-
image pain usually appears when tumors are at an
advanced stage.
Conclusions
Downregulated Nav1.8 expression was observed in DRG
neurons in a cancer pain model induced by inoculation
with Walker 256 breast carcinosarcoma cells. Moreover,
knockdown of Nav1.8 expression attenuated cancer pain
behavior. These findings suggest that Nav1.8 can contrib-
ute to the development and maintenance of bone cancer
pain. Nav1.8 could be a potential target for treatment of
bone cancer pain induced by metastatic breast cancer
cells.
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